128 related articles for article (PubMed ID: 36964649)
1. Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosis.
Xing J; Chen J; You T; Sun Z; Lu T; Cheng Y; Wu H; Bai C
J Neuroendocrinol; 2023 Apr; 35(4):e13257. PubMed ID: 36964649
[TBL] [Abstract][Full Text] [Related]
2. Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
Bean GR; Najjar S; Shin SJ; Hosfield EM; Caswell-Jin JL; Urisman A; Jones KD; Chen YY; Krings G
Mod Pathol; 2022 Oct; 35(10):1349-1361. PubMed ID: 35590107
[TBL] [Abstract][Full Text] [Related]
3. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
[TBL] [Abstract][Full Text] [Related]
5. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
6. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
Hacking SM; Yakirevich E; Wang Y
J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
[TBL] [Abstract][Full Text] [Related]
7. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and genetic characteristics of gastric neuroendocrine tumour (NET) G3 and comparisons with neuroendocrine carcinoma and NET G2.
Chen S; Sun L; Chen H; Li J; Lu C; Yang Y; Sun Y
Histopathology; 2023 Nov; 83(5):700-711. PubMed ID: 37403531
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
11. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
12. The neuroendocrine carcinoma component of gastric mixed adenoneuroendocrine carcinoma could develop with MLH1 deficiency independent of TP53 mutation.
Hashimoto R; Matsusaka K; Matsumura T; Hayano K; Kato N; Matsubara H; Ikeda JI
Pathol Int; 2023 Jun; 73(6):261-263. PubMed ID: 37067391
[No Abstract] [Full Text] [Related]
13. Implication of cytoplasmic p53 expression in pulmonary neuroendocrine carcinoma using next-generation sequencing analysis.
Jimbo N; Ohbayashi C; Fujii T; Takeda M; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
Histopathology; 2024 Jan; 84(2):336-342. PubMed ID: 37814580
[TBL] [Abstract][Full Text] [Related]
14. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 and RB proteins in squamous cell carcinoma of the esophagus: their relationship with clinicopathologic characteristics.
Hashimoto N; Tachibana M; Dhar DK; Yoshimura H; Nagasue N
Ann Surg Oncol; 1999; 6(5):489-94. PubMed ID: 10458688
[TBL] [Abstract][Full Text] [Related]
16. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
19. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
Tan HL; Sood A; Rahimi HA; Wang W; Gupta N; Hicks J; Mosier S; Gocke CD; Epstein JI; Netto GJ; Liu W; Isaacs WB; De Marzo AM; Lotan TL
Clin Cancer Res; 2014 Feb; 20(4):890-903. PubMed ID: 24323898
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center.
Shafi S; Hu Y; Parwani AV; Ding Q; Li Z
Breast Cancer Res Treat; 2022 Dec; 196(3):463-469. PubMed ID: 36260193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
